

Version 3c Last updated 21 April 2026

# **ab237658 anti-Bevacizumab (Human) ELISA Kit**

For the measurement of the antibody against Bevacizumab in human serum and plasma.

This product is for research use only and is not intended for diagnostic use.

## Table of Contents

|                                           |    |
|-------------------------------------------|----|
| 1. Overview                               | 3  |
| 2. Protocol Summary                       | 4  |
| 3. Precautions                            | 5  |
| 4. Storage and Stability                  | 5  |
| 5. Limitations                            | 5  |
| 6. Materials Supplied                     | 6  |
| 7. Materials Required, Not Supplied       | 6  |
| 8. Technical Hints                        | 7  |
| 9. Reagent Preparation                    | 7  |
| 10. Standard and Control Preparation      | 8  |
| 11. Sample Preparation                    | 8  |
| 12. Confirmation test mixture preparation | 8  |
| 13. Assay Procedure                       | 9  |
| 14. Calculations                          | 9  |
| 15. Typical Data                          | 11 |
| 16. Typical Sample Values                 | 11 |
| 17. Notes                                 | 12 |

## 1. Overview

anti-Bevacizumab ELISA Kit (ab237658) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Bevacizumab in biological matrices such as human serum and plasma.

Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. It has been demonstrated that bevacizumab, in combination with chemotherapy, resulted in increased survival in patients with previously untreated metastatic colorectal cancer relative to chemotherapy alone, leading to FDA approval of the first anti-angiogenic agent. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

## 2. Protocol Summary

Prepare all reagents, samples, and standards as instructed



Add 100  $\mu$ L standard, controls, diluted sample and confirmation test mixture to appropriate wells. Cover and incubate for 60 minutes at room temperature



Discard incubation solution and wash plate 3 times with 300  $\mu$ L diluted Wash Buffer



Add 100  $\mu$ L peroxidase conjugate to each well. Cover and incubate for 60 minutes at room temperature



Discard the solution and wash plate 3 times with 300  $\mu$ L diluted Wash Buffer



Add 100  $\mu$ L TMB Substrate and incubate the plate in the dark at room temperature for 20 minutes.



Add 100  $\mu$ L Stop Solution and read OD at 450 nm within 20 minutes.

### 3. Precautions

**Please read these instructions carefully prior to beginning the assay.**

- If applicable, please refer to the current Safety Data Sheet (SDS) provided with this product for safety, handling, and disposal information. The most up to date and current versions are available on our website <https://www.abcam.com/en-us>
- Observe good laboratory practices. Gloves, lab coat, and protective eyewear should always be worn. Never pipet by mouth. Do not eat, drink or smoke in the laboratory areas.
- For general guidelines, precautions, limitations on the use of our assay kits and general assay troubleshooting tips, particularly for first time users, please consult our guide: [www.abcam.com/assaykitguidelines](http://www.abcam.com/assaykitguidelines)

### 4. Storage and Stability

**Store kit at +4°C immediately upon receipt. Kit has a storage time of 1 year from receipt, providing components have not been reconstituted.**

Refer to list of materials supplied for storage conditions of individual components.

### 5. Limitations

- Assay kit intended for research use only. Not for use in diagnostic procedures.
- Do not mix or substitute reagents or materials from other kit lots or vendors.

## 6. Materials Supplied

| Item                    | Quantity | Storage condition |
|-------------------------|----------|-------------------|
| Micro ELISA Plate       | 1 unit   | +4°C              |
| Bevacizumab Standard S1 | 1 mL     | +4°C              |
| Bevacizumab Standard S2 | 1 mL     | +4°C              |
| Bevacizumab Standard S3 | 1 mL     | +4°C              |
| Bevacizumab Standard S4 | 1 mL     | +4°C              |
| Bevacizumab Standard S5 | 1 mL     | +4°C              |
| Bevacizumab Standard S6 | 1 mL     | +4°C              |
| Control – low level     | 1 mL     | +4°C              |
| Control – high level    | 1 mL     | +4°C              |
| Confirmation Reagent    | 12 mL    | +4°C              |
| Assay Buffer            | 50 mL    | +4°C              |
| Peroxidase Conjugate    | 12 mL    | +4°C              |
| TMB Substrate           | 12 mL    | +4°C              |
| Stop Solution           | 12 mL    | +4°C              |
| Wash Buffer (20X)       | 50 mL    | +4°C              |
| Plate sealers           | 2 units  | +4°C              |

## 7. Materials Required, Not Supplied

These materials are not included in the kit, but will be required to successfully perform this assay:

- Microplate reader capable of measuring absorbance at OD 450 nm
- Deionized water.
- Multi- and single-channel pipettes.
- Tubes for sample dilution.
- Plate shaker for all incubation steps.
- Absorbent paper

## 8. Technical Hints

- Samples generating values higher than the highest standard should be further diluted.
- Avoid foaming or bubbles when mixing or reconstituting components.
- Avoid cross contamination of samples or reagents by changing tips between sample, standard and reagent additions.
- Ensure plates are properly sealed or covered during incubation steps.
- Complete removal of all solutions and buffers during wash steps is necessary to minimize background.
- All samples should be mixed thoroughly and gently.
- Avoid multiple freeze/thaw of samples.
- Incubate ELISA plates on a plate shaker during all incubation steps.
- When generating positive control samples, it is advisable to change pipette tips after each step.

## 9. Reagent Preparation

- Equilibrate all reagents to room temperature (18-25°C) prior to use. Before using the kit, spin tubes and bring down all components to the bottom of tubes.
- Prepare only as much reagent as is needed on the day of the experiment.

### 9.1 20X Wash Buffer:

Dilute the 20X Wash Buffer to 1X solution in ddH<sub>2</sub>O (10 mL of Wash Buffer stock to 190 mL of ddH<sub>2</sub>O). Warm up 37°C to dissolve crystals. Mix the 1X solution thoroughly by vortex manually. The working stock can be stable for 2 weeks after preparation at 4°C.

## 10. Standard and Control Preparation

Standard and controls, S1 – S6 and controls, are ready to use, please see table below for standard concentrations:

| Name           | S1  | S2 | S3 | S4 | S5 | S6 |
|----------------|-----|----|----|----|----|----|
| Conc.<br>ng/mL | 160 | 80 | 40 | 20 | 10 | 0  |

Concentration for high and low controls are indicated on vials.

## 11. Sample Preparation

### General sample information:

- We recommend performing several dilutions of your sample to ensure the readings are within the standard value range.
- We recommend that you use fresh samples for the most reproducible assay.

### 11.1 Serum/plasma:

1. Dilute samples at 1:10 (20 µL serum/plasma + 180 µL assay buffer) or 1:100 (5 µL serum/plasma + 495 µL ddH<sub>2</sub>O).
2. Diluted samples should further be diluted if the concentration of Bevacizumab is higher than the measuring range.
3. Samples are stable at 4°C for 7 days and -20°C for 6 months. Avoid freeze-and-thaw cycle.

**Δ Note:** The usual precautions for venipuncture should be observed.

## 12. Confirmation test mixture preparation

Mix 10 µL sample (serum/plasma) with 90 µL of confirmation reagent for 60 minutes in a microtube prior to the test.

## 13. Assay Procedure

- Prepare reagents within 30 minutes before the experiment.
- Equilibrate all materials and prepared reagents to room temperature 15 minutes prior to use.
- We recommend that you assay all standards, controls and samples in duplicate.

- 13.1** Add 100  $\mu$ L of standards, controls, diluted samples and confirmation test mixture into appropriate wells. Cover wells and incubate for 60 minutes at room temperature.
- 13.2** Discard incubation solution. Wash plate 3 times each with 300  $\mu$ L of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
- 13.3** Add 100  $\mu$ L of Peroxidase Conjugate into each well. Cover wells with adhesive plate sealer and incubate at room temperature for 60 minutes.
- 13.4** Discard the solution and wash the wells as step 13.2.
- 13.5** Add 100  $\mu$ L of 1X TMB substrate solution and incubate the plate in the dark at room temperature for 20 minutes.
- 13.6** Add 100  $\mu$ L of Stop solution to stop the reaction.
- 13.7** Read the absorbance in a microplate reader set to 450 nm within 20 minutes. (Reference wavelength to 650 nm).

## 14. Calculations

### 14.1 Quantitative Calculation

- 14.1.1 Calculate the average absorbance value for the blank control (0 ng/mL) standards. Subtract the average blank control standard absorbance value from all other absorbance values.
- 14.1.2 **Create a standard curve** by plotting the average blank control subtracted absorbance value for each standard concentration (y axis) against the target protein concentration (x axis) of the standard.
- 14.1.3 Construct a standard curve of difference data using software capable of generating four-parameter logistic (4PL) or point-to-point calculation curve fit.

- 14.1.4 To obtain the exact values of the samples, the concentration determined from the standard curve should be multiplied by the dilution factor.
- 14.1.5 Determine the concentration of the target protein in the sample by interpolating the blank control subtracted **absorbance values against the standard curve**. Multiply the resulting value by the appropriate dilution factor to obtain the concentration of target protein in the sample.
- 14.1.6 Samples generating absorbance values greater than that of the highest standard should be further diluted and reanalyzed. Similarly, samples which measure at an absorbance values less than that of the lowest standard should be retested in a less dilute form.


## 14.2 Qualitative Interpretation

- 14.2.1 If "Sample OD450/650 / Zero Standard (S5) OD450/650" is < 3, the sample is NEGATIVE for Antibody to Bevacizumab (ATR).
- 14.2.2 If "Sample OD450/650 /Zero Standard (S5) OD450/650" is ≥3, the sample is POSITIVE for ATR, and if required samples may be extrapolated for quantitative analysis and confirmation.
- 14.2.3 For the run to be valid, the OD450/650 nm of High Control should be ≥ 1.000 and the OD450/650 nm of each Low Control should be <0.200, if not, improper technique or reagent deterioration may be suspected and the run should be repeated.
- 14.2.4 Interpretation of true and false positive: For true positive sample, inhibition should be equal or greater than 25%.

$$\frac{OD\ sample - OD\ sample\ with\ confirmation\ reagent}{OD\ sample} \times 100 = inhibition\ \%$$

## 15. Typical Data

Typical standard curve - data provided **for demonstration purposes only**. A new standard curve must be generated for each assay performed.



**Figure 1.** Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.

## 16. Typical Sample Values

**Sensitivity:** 7.5 ng/mL.

**Assay Precision:** Intra-Assay CV < 30%; Inter-Assay: CV < 30% (CV (%) = SD/mean X 100)

**Cross Reactivity:** Bevacizumab infusion camouflages/masks the presence of antibody to Bevacizumab (ATA) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATA. It is convenient to obtain blood sample just before the infusion of Bevacizumab or at least 2 weeks after the infusion of Bevacizumab.

**Recovery rate:** <100±30% with normal human serum samples with known concentrations.

## 17. Notes

## **Technical Support**

Copyright © 2026 Abcam. All Rights Reserved. The Abcam logo is a registered trademark. All information / detail is correct at time of going to print.

For all technical or commercial enquiries please go to:

<https://www.abcam.com/en-us/contact-us>

<https://www.abcam.cn/contact-us> (China)

<https://www.abcam.co.jp/contact-us> (Japan)